ArticleAmerican journal of hematology2026
Comparative Effectiveness of Oral Anticoagulants and Home Time After Venous Thromboembolism in Frail and Non-Frail Older Adults.
Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In this retrospective cohort of 18 066 Medicare fee-for-service beneficiaries ≥ 65 years with acute VTE (2015-2019), we compared apixaban, rivaroxaban, and warfarin using propensity score (PS) overlap weighting and intention-to-treat analyses across total, non-frail, and frail strata defined by a claims-based frailty index. After PS weighting (all SMDs < 0.10), apixaban versus warfarin was associated with a lower 1-year composite of recurrent VTE or death in the total population (189.1 versus 216.1 per 1000 PY; HR 0.86, 95% CI 0.77-0.96), with benefit evident in non-frail patients (114.5 versus 143.6; HR 0.78, 0.66-0.92) and attenuated in frail patients (330.9 versus 349.9; HR 0.93, 0.82-1.07). Recurrent VTE rates favored apixaban but were not statistically significant overall (40.5 versus 54.8; HR 0.86, 0.68-1.08). Major bleeding was lower with apixaban (19.4 versus 26.0; HR 0.73, 0.53-1.00). Home-time loss was reduced with apixaban compared with warfarin in the total population (mean 54.9 versus 67.0 days; RR 0.89, 0.83-0.96) and was directionally similar across both frailty strata. Rivaroxaban showed no clear advantage over warfarin for the composite (216.9 versus 216.1; HR 1.00, 0.90-1.11) or bleeding (HR 0.99, 0.73-1.32) and yielded greater home-time loss than apixaban (RR 1.08, 1.01-1.17). Overall, apixaban demonstrated the most favorable balance of effectiveness, safety, and patient-centered benefit, with patterns generally consistent across frailty levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.